EMERYVILLE, CA & SHANGHAI / ACCESSWIRE / NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, and China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of premium branded pharmaceutical products and medical devices in China, today announced that Taiwan’s Food and Drug Administration has cleared NovaBay’s NeutroPhase(R) Skin and Wound Cleanser for sale in Taiwan. NovaBay will be shipping NeutroPhase to Taiwan in the fourth quarter of 2014 to support Pioneer’s launch of the product in early 2015.
“The clearance by the country’s regulators is yet another confirmation of the safety and potential medical benefits of NeutroPhase,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “It also continues our expansion throughout Asia.”
NeutroPhase previously has been cleared for sale throughout mainland China, Singapore, Malaysia and the United States.
Pioneer Pharma will be working with a local distributer to sell the product in Taiwan. “This will give physicians in Taiwan a new tool in managing chronic non-healing wounds, such as diabetic ulcers, and in treating acute infections like flesh-eating disease,” said Paul Li (Mr. Li Xinzhou), Chairman, Executive Director and Chief Executive Officer of Pioneer Pharma.
NeutroPhase contains Neutrox(TM), NovaBay’s proprietary, manufactured pure hypochlorous acid solution which mimics a substance produced naturally by the immune system as a first defense against microbial invaders. Laboratory tests show that Neutrox not only kills bacteria that infect wounds and cause necrotizing fasciitis, it also neutralizes toxins produced by both bacteria and the immune system that impede healing and destroy healthy tissue. Those properties enable NeutroPhase to be useful as an advanced wound cleanser in the management of acute and chronic infections, allowing the body to progress toward healing.
Physicians like Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, Calif, Dr. Anibal Gauto of Eisenhower Medical Center and Dr. Kerry Thibodeaux of Opelousas General Health System and many others already routinely manage diabetic ulcers with NeutroPhase. Dr. Crew has also developed a method of irrigating flesh-eating wounds with NeutroPhase; his treatment regime has been remarkably successful in saving the lives and limbs of victims of this life-threatening disease, as Crew and NovaBay researchers reported in the journal WOUNDS.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics(R)
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide(R) compounds, led by auriclosene, and its Hypochlorous Solution Family of Products: NeutroPhase(R) for wound care, Advanced i-Lid(TM) Cleanser for the eye care market, and CelleRx(TM) for the dermatology market.
China Pioneer Pharma is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China, Founded in 1996, which has an 18-year operating history. Currently, China Pioneer Pharma has a product portfolio of over 30 pharmaceutical products covering a wide range of therapeutic areas, and medical devices covering four medical specialties. And it has over 240 in-house marketing and promotion employees, over 1,000 third-party promotion partners and over 500 distributors. China Pioneer Pharma sold its products through its nationwide marketing, promotion and channel management service network to a total of over 26,000 hospitals and other medical institutions and over 95,000 pharmacies across 31 provinces, municipalities and autonomous regions in China. For more information, please visit www.pioneer-pharma.com.
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding regulatory approvals for our products, the anticipated market acceptance of our products, and the company’s expected future financial results. The words “will” “estimated” “anticipate” and “expect” are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in product development, clinical trials, regulatory approval, production and marketing of the company’s products, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For NovaBay NeutroPhase purchasing information:
Contact a NeutroPhase Distributor
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson